AGLEライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (28 11月 2023 @ 06:00):

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases...

Stats
本日の出来高	43 238.00
平均出来高	59 537.00
時価総額	48.63M
EPS	$0 ( 2024-03-07 )
次の収益日	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.162
ATR14	$2.39 (12.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-29	Fairmount Funds Management Llc	Buy	406 038	Common Stock
2023-12-29	Fairmount Funds Management Llc	Sell	3 435 480	Common Stock
2023-12-22	Burrows Scott L	Buy	134 953	Common Stock
2023-12-07	Fairmount Funds Management Llc	Buy	16 667	Series B Preferred Stock
2023-11-22	Albers Jeffrey W.	Buy	50 000	Stock Option (Right to Buy)

INSIDER POWER
-5.28
Last 85 transactions
Buy: 64 136 392 \| Sell: 71 129 759

ボリューム相関

長: 0.44 (neutral)

短: -0.73 (moderate negative)

Signal:(64.735) Neutral

Aeglea Bio Therapeutics 相関

10 最も正の相関
GAINL	0.987
RETA	0.975
PRVB	0.967
ULBI	0.966
RDUS	0.964
SQL	0.96
HURN	0.948
CSSE	0.946
SONN	0.945
SGMO	0.945

10 最も負の相関
BOCH	-0.967
LMRK	-0.964
SBNYP	-0.962
SHSP	-0.956
TIOA	-0.944
MSDA	-0.941
ANIK	-0.939
MSDAU	-0.938
SKYA	-0.938
QADA	-0.937

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Aeglea Bio Therapeutics 相関 - 通貨/商品

0.45
( neutral )

0.68
( moderate )

-0.01
( neutral )

0.66
( moderate )

-0.79
( moderate negative )

-0.36
( neutral )

Aeglea Bio Therapeutics 財務諸表

Annual	2022
収益:	$2.33M
総利益:	$2.33M (100.00 %)
EPS:	$-24.86

FY	2022
収益:	$2.33M
総利益:	$2.33M (100.00 %)
EPS:	$-24.86

FY	2021
収益:	$18.74M
総利益:	$0.00 (0.00 %)
EPS:	$-1.233

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.520

Financial Reports:

No articles found.

Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.